CMPS — COMPASS Pathways plc

Summary of COMPASS Pathways Q3 2025 Earnings Call

1. Key Financial Results and Metrics:

• Cash and cash equivalents at the end of September stood at $186 million, down from $222 million in Q2 2025.
• Cash used in operations for Q3 was $35 million; full-year net cash usage is expected to be between $120 million and $145 million.
• Debt under the Hercules loan facility was $31.3 million.

2. Strategic Updates and Business Highlights:

• COMPASS announced a 9- to 12-month acceleration of its launch plans for COMP360, following positive results from the Phase III trial COMP005.
• Enrollment for the second Phase III trial, COMP006, has been completed, with data readouts expected in Q1 2026.
• The company is preparing for a potential rolling NDA submission with the FDA, which may include unblinding 9-week data from COMP006 alongside 26-week data from COMP005.
• Strategic collaborations and commercial preparations are ongoing, focusing on understanding the market landscape and provider dynamics in interventional psychiatry.

3. Forward Guidance and Outlook:

• The company anticipates the 26-week data from COMP006 to be the final gating item for NDA submission, expected in early Q3 2026.
• COMPASS is optimistic about its ability to launch COMP360, targeting the 3 million individuals in the U.S. with treatment-resistant depression (TRD).
• Plans for a late-stage PTSD trial are being finalized, with updates expected soon.

4. Bad News, Challenges, or Points of Concern:

• The decline in cash reserves from the previous quarter raises concerns about financial sustainability as the company continues to burn cash.
• The uncertainty surrounding the timing of the R&D tax credit in the U.K. could impact cash flow.
• While the FDA has been supportive, the company must still meet high regulatory standards, which could pose risks if data does not align with expectations.

5. Notable Q&A Insights:

• The selection of a specialty pharma partner for patient access is still in progress, with no decisions made yet.
• COMPASS believes that sites currently administering SPRAVATO will likely be able to deliver COMP360 without significant changes.
• The company is preparing for potential FDA advisory committee meetings, contingent on the timing of data submissions.
• Discussions with the VA regarding access to COMP360 have been positive, indicating a proactive approach to integrating psychedelic treatments in veteran care.
• The management emphasized that the completion of enrollment in COMP006 and the positive FDA interactions were key factors in accelerating timelines.

Overall, COMPASS Pathways is positioned for significant developments in the coming year, with a focus on regulatory compliance, strategic partnerships, and market readiness for COMP360.